Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

To gain a better understanding of the role of somatic mutations in olaparib response, next-generation sequencing (NGS) of BRCA1 and BRCA2 was performed as part of a planned retrospective analysis of tumors from a randomized, double-blind, Phase II trial (Study 19; D0810C00019; NCT00753545) in 265 pa...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Dougherty, Brian A., Lai, Zhongwu, Hodgson, Darren R., Orr, Maria C.M., Hawryluk, Matthew, Sun, James, Yelensky, Roman, Spencer, Stuart K., Robertson, Jane D., Ho, Tony W., Fielding, Anitra, Ledermann, Jonathan A., Barrett, J. Carl
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Priority Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546431/
https://ncbi.nlm.nih.gov/pubmed/28525389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17613
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki